<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03824041</url>
  </required_header>
  <id_info>
    <org_study_id>18-8045H</org_study_id>
    <nct_id>NCT03824041</nct_id>
  </id_info>
  <brief_title>Effects of Aronia Berries on Vascular Endothelial Function and the Gut Microbiota in Middle-Aged/Older Adults</brief_title>
  <official_title>Aronia Berry Supplementation for Improving Vascular Endothelial Dysfunction and Modulating the Gut Microbiota in Middle-Aged/Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naturex-Dbs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Colorado State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aging is the primary risk factor for cardiovascular disease (CVD) largely due to vascular&#xD;
      endothelial dysfunction, a major initial step in the development of atherosclerosis.&#xD;
      Endothelial dysfunction is characterized by impaired endothelium-dependent dilation and is&#xD;
      primarily caused by reduced nitric oxide bioavailability secondary to oxidative stress and&#xD;
      inflammation. Interventions that improve endothelial dysfunction are important for improving&#xD;
      endothelial function and reducing CVD risk in this high-risk population. Aronia melanocarpa,&#xD;
      commonly known as aronia berries or chokeberries, are rich in polyphenols such as&#xD;
      anthocyanins, proanthocyanidins, and phenolic acids. These compounds, and derivatives&#xD;
      resulting from gut microbial and phase II metabolism, have been shown to attenuate oxidative&#xD;
      stress and inflammation, and to improve endothelial function. Aronia berries and other&#xD;
      berries have been shown in numerous studies to have diverse cardiometabolic health effects&#xD;
      including modulation of endothelial function, arterial stiffness, blood pressure, oxidative&#xD;
      stress, and inflammation. In addition, berries, dietary fiber, polyphenols have been shown to&#xD;
      exert positive effects on the gut microbiota, which may mediate improvements in&#xD;
      cardiovascular health. Recently, we have demonstrated that modulation of the gut microbiota&#xD;
      is associated with improvements in vascular dysfunction. The primary goal of the currently&#xD;
      proposed research is to assess the efficacy and dose-dependent response of an aronia full&#xD;
      spectrum dietary supplement to improve endothelial function in middle-aged/older men and&#xD;
      postmenopausal women. A secondary goal is to determine whether aronia full spectrum&#xD;
      modulation of the gut microbiota is associated with improvements in endothelial function.&#xD;
      Other functional and biochemical measures of cardiovascular health, oxidative stress,&#xD;
      inflammation, and polyphenol metabolism will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline reactive hyperemia index (RHI) after 6 weeks consumption</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on RHI measured by EndoPAT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota analysis</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on stool sample microbial populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on brachial and aortic blood pressure measured by SphygmoCor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation index</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on augmentation index measured by SphygmoCor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal health</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on gastrointestinal health using a validated questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on aortic arterial stiffness measured by SphygmoCor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on blood lipid profiles (total cholesterol, HDL, LDL, triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood hemoglobin A1c</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on Hemoglobin A1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood oxidized LDL</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on oxidized LDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood ICAM</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on ICAM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood VCAM</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on VCAM</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma polyphenol metabolites</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on plasma polyphenol metabolites</description>
  </other_outcome>
  <other_outcome>
    <measure>Fecal polyphenol metabolites</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on fecal polyphenol metabolites</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine polyphenol metabolites</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Determine the effects on urine polyphenol metabolites</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Formulation containing inert artificially colored maltodextrin, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aronia full spectrum - half dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation containing 50% Aronia full spectrum and 50% placebo, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aronia full spectrum - full dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation of 100% Aronia full spectrum, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aronia full spectrum - half dose</intervention_name>
    <description>Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)</description>
    <arm_group_label>Aronia full spectrum - half dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aronia full spectrum - full dose</intervention_name>
    <description>Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)</description>
    <arm_group_label>Aronia full spectrum - full dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and postmenopausal women (&gt; 1 year from cessation of menstruation)&#xD;
&#xD;
          -  Aged 45-75 years&#xD;
&#xD;
          -  Baseline endothelial dysfunction (RHI ≤ 1.67)&#xD;
&#xD;
          -  Hemoglobin A1C ≤ 6.4%&#xD;
&#xD;
          -  Blood pressure &lt; 129/80 mmHg&#xD;
&#xD;
          -  Total cholesterol &lt; 240 mg/dL&#xD;
&#xD;
          -  LDL cholesterol &lt; 190 mg/dL&#xD;
&#xD;
          -  Triglycerides &lt; 350&#xD;
             mg/dLhttps://register.clinicaltrials.gov/prs/app/template/Home.vm?uid=U00036MD&amp;ts=50&amp;s&#xD;
             id=S0008GBU&amp;cx=gvt3fw&#xD;
&#xD;
          -  Body mass index ≥ 18.5 and &lt; 30 kg/m2&#xD;
&#xD;
          -  Subjects are willing to maintain their normal eating/drinking habits and exercise&#xD;
             habits to avoid changes in body weight over the duration of the study&#xD;
&#xD;
          -  Are able to understand the nature of the study&#xD;
&#xD;
          -  Able and willing to give signed written informed consent&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals taking antihypertensive, lipid-lowering, and/or hormone replacement&#xD;
             medications&#xD;
&#xD;
          -  Diagnosed hypertension, CVD, diabetes, metabolic syndrome, cancer, kidney, liver,&#xD;
             pancreatic disease&#xD;
&#xD;
          -  Obese participants, defined as BMI superior or equal to 30&#xD;
&#xD;
          -  Neuropathy, thrombosis, or past arm trauma or surgery&#xD;
&#xD;
          -  &gt; 3 days/wk vigorous exercise&#xD;
&#xD;
          -  Participating in a weight loss program&#xD;
&#xD;
          -  Weight change &gt; 5% in the past 3 months&#xD;
&#xD;
          -  Current smokers or history of smoking in the last 12 months&#xD;
&#xD;
          -  Heavy drinkers (&gt; 7 drinks/wk for women; &gt;14 drinks/wk for men)&#xD;
&#xD;
          -  Antibiotic use at any point during the study or two months prior to enrollment&#xD;
&#xD;
          -  Allergies to aronia berries or other study materials&#xD;
&#xD;
          -  Unwillingness to maintain normal diet and/or physical activity pattern, or to&#xD;
             discontinue use of dietary supplements for the duration of the study&#xD;
&#xD;
          -  Any reason or condition that in the judgment of the clinical investigator(s) may put&#xD;
             the subject at unacceptable risk or that may preclude the subject from understanding&#xD;
             or complying with the study's requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah A Johnson, PhD, RDN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Food Science and Human Nutrition, Colorado State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Food Science and Human Nutrition, Colorado State University</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80523-1571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>May 9, 2021</last_update_submitted>
  <last_update_submitted_qc>May 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyphenols</keyword>
  <keyword>Anthocyanins</keyword>
  <keyword>Vascular function</keyword>
  <keyword>Gut microbiome</keyword>
  <keyword>Gut health</keyword>
  <keyword>Berries</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

